Abera Bioscience
A vaccine plattform company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | SEK4.7m | Grant | |
| Total Funding | 000k | ||
| SEK | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | (46 %) | 46 % | 55 % | 43 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (164 %) | (446 %) | (770 %) | (1048 %) | (632 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Abera Bioscience is a pioneering platform and vaccine development company, leveraging over three decades of research in the medical, molecular, and microbiological fields. Founded in 2012 as a spin-out from the Swedish protein production company Xbrane Bioscience, Abera Bioscience has been at the forefront of developing novel vaccine delivery platforms. The company's core technology involves displaying antigenic proteins on bacterial surfaces, which has been instrumental in creating experimental vaccines against diseases such as pneumococcal disease, chlamydia, ETEC, and tuberculosis.
Abera Bioscience operates in the biotechnology and pharmaceutical markets, primarily serving academic institutions, biotech firms, and healthcare providers. The company collaborates extensively with academia and the biotech industry to refine its platform and develop new vaccines. Its business model revolves around research and development, with revenue generated through partnerships, grants, and licensing agreements.
The recent addition of PhD Sohila Zadran, a seasoned entrepreneur and venture capitalist, to the board underscores Abera Bioscience's commitment to strengthening its leadership and expanding its strategic capabilities.
Keywords: vaccine development, antigenic proteins, bacterial surfaces, biotechnology, pharmaceutical, research collaboration, experimental vaccines, pneumococcal disease, chlamydia, tuberculosis.